US 12,357,692 B2
Method of treating influenza A
Nicole Kallewaard-Lelay, Gaithersburg, MD (US); Raburn Mallory, Gaithersburg, MD (US); Gabriel Robbie, Gaithersburg, MD (US); and Song Ren, Gaithersburg, MD (US)
Assigned to MEDIMMUNE, LLC, Gaithersburg, MD (US)
Filed by MEDIMMUNE, LLC, Gaithersburg, MD (US)
Filed on Dec. 9, 2022, as Appl. No. 18/063,902.
Application 18/063,902 is a continuation of application No. 16/984,827, filed on Aug. 4, 2020, granted, now 11,547,756.
Application 16/984,827 is a continuation of application No. 16/068,941, abandoned, previously published as PCT/US2017/013086, filed on Jan. 12, 2017.
Claims priority of provisional application 62/278,068, filed on Jan. 13, 2016.
Prior Publication US 2023/0181735 A1, Jun. 15, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/42 (2006.01); A61K 31/13 (2006.01); A61K 31/215 (2006.01); A61K 31/7012 (2006.01); A61P 31/16 (2006.01); C07K 16/10 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/42 (2013.01) [A61K 31/13 (2013.01); A61K 31/215 (2013.01); A61K 31/7012 (2013.01); A61P 31/16 (2018.01); C07K 16/1018 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/21 (2013.01); C07K 2317/33 (2013.01); C07K 2317/76 (2013.01); C07K 2317/94 (2013.01); C12N 2760/16111 (2013.01)] 13 Claims
 
1. A method of preventing an influenza A virus symptom in a patient, the method comprising administering to the patient about 3000 mg anti-influenza A antibody or fragment thereof that is capable of binding to influenza A virus hemagglutinin and neutralizing at least one group 1 subtype and at least one group 2 subtype of influenza A virus, wherein the anti-influenza A antibody or fragment thereof comprises a HCDR1 of SEQ ID NO:3, HCDR2 of SEQ ID NO:4, and HCDR3 of SEQ ID NO:5 and a LCDR1 of SEQ ID NO:8, LCDR2 of SEQ ID NO:9 and LCDR3 of SEQ ID NO:10.